Navigation Links
Jazz Pharmaceuticals Announces Public Offering of Common Stock
Date:5/10/2010

PALO ALTO, Calif., May 10 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.  All of the shares in the offering are to be sold by Jazz Pharmaceuticals. Barclays Capital Inc. is the sole book-running manager of the offering. Jazz Pharmaceuticals intends to use all of the net proceeds from the offering to repay a portion of its outstanding senior secured notes.  

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted.  Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from: Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and related prospectus supplements, and the other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering.  You may access these documents when available for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the completion of the public offering. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to completion of the public offering. There can be no assurance that Jazz Pharmaceuticals will be able to complete the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the heading "Risk Factors" in Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed with the Securities and Exchange Commission (SEC) on May 6, 2010, and in the preliminary prospectus supplement related to the public offering to be filed with the SEC on May 10, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province
2. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
4. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
5. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
6. DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
7. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
8. ADVENTRX Pharmaceuticals Announces Closing of Financing
9. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
10. Trading Halted Today in Questcor Pharmaceuticals Common Stock
11. HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016 Potrero ... system, is pleased to announce the appointment of George ... San Antonio, TX , WellMed is ... servicing over 200,000 patients and HMO members in ... founding WellMed in 1990 out of his own internal medicine ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting that ... alcohol abstinence for all women who are at risk ... U.S. each year and raises the risks of unprotected ... --> According to the Guttmacher Institute, there ... women of child-bearing age, who have sex without the ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into ... partners to offer real-time business intelligence (BI) to their small and medium business ...
(Date:2/12/2016)... Washington, NC (PRWEB) , ... February 12, 2016 , ... ... the surrounding areas, is initiating a charity drive that will raise funds earmarked to ... at John C. Tayloe Elementary School. , “My school is in a low-income area ...
(Date:2/12/2016)... ... ... Erlanger Agency has announced a new partnership in its ongoing community involvement program ... fight against breast cancer, fundraising for a local woman named Carmen, who is currently ... a loving single mother of two boys who also serves as caregiver for her ...
(Date:2/12/2016)... ... ... Miami Dental Specialists is excited to bring patients the choice of ceramic, ... Miami Dental Specialists will offer the non-metal implants as a safe, holistic and hygienic ... by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to Miami. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
Breaking Medicine News(10 mins):